Lifeboat Foundation

Rates of anxiety and depression have been increasing around the world for decades, a trend that has been sharply exacerbated by the COVID-19 pandemic. New research led by the Boyce Thompson Institute’s Frank Schroeder could ultimately lead to new therapeutics to help relieve this global mental health burden.

First discovered in the 1930s, serotonin is a neurotransmitter produced in many animals that mediates myriad behaviors, such as feeding, sleep, mood and cognition. Drugs that alter serotonin levels are the main weapon to treat psychological conditions like anxiety and depression, as well as eating disorders.

As a simple model for neurobiology research, the microscopic roundworm Caenorhabditis elegans has been used extensively to study serotonin’s role in regulating behavior and food intake. For many years, researchers thought that serotonin was made in C. elegans by one specific molecular pathway, and that serotonin was then quickly degraded. Schroeder’s team and colleagues at Columbia University now demonstrated that both of those assumptions were not quite correct.

What is limb regeneration and what species possess it? How is it achieved? What does this tell us about intelligence in biological systems and how could this information be exploited to develop human therapeutics? Well, in this video, we discuss many of these topics with Dr Michael Levin, Principal Investigator at Tufts University, whose lab studies anatomical and behavioural decision-making at multiple scales of biological, artificial, and hybrid systems.

Find Michael on Twitter — https://twitter.com/drmichaellevin.

Continue reading “Regeneration, Intelligence in Life & Memory — Dr Michael Levin” »

VINS Bioproducts Limited, Hyderabad in collaboration with the Centre for Cellular and Molecular Biology (CCMB) and the University of Hyderabad (UoH), announced the successful completion of Phase 2 clinical trials of VINCOV-19, India’s first antidote and cure against SARS-CoV-2 virus.

VINCOV-19 is now ready for market authorisation and for simultaneous Phase 3 clinical trials.

Continue reading “VINCOV-19, an antidote, and a cure against COVID-19 completes Phase 2 clinical trials” »

A small California biotech emerged from stealth last year to go after drug discovery’s “data problem,” and now the AI outfit has announced its first public partnership. Terray Therapeutics put out word Wednesday that it reached a deal with Calico Life Sciences, the Google-backed anti-aging biotech co-founded by industry legend.

When lab-grown clumps of human neurons are transplanted into newborn rats, they grow with the animals. The research raises some tricky ethical questions.

By packaging lipid nanoparticles with elements that decrease the fibrous nature of solid tumors, researchers can deliver CRISPR therapies in a more efficient manner.

Celine halioua drops into a crouch and greets Bocce, a Chihuahua-dachshund mix with soulful brown eyes, like a long-lost friend. “Oh my God, you’re so beautiful!” she chirps. The two have just met in an upstairs room at Muttville Senior Dog Rescue in San Francisco, where light streams in through the open windows and urine occasionally streams onto the floor. About a dozen elderly dogs, none taller than a kneecap, putter around on the gray linoleum or nap on blankets. When Halioua kneels, her dark hair tumbling over her shoulder, Bocce rests his head blissfully in her lap.

A tragedy of human-canine relations is that a 10-year-old dog such as Bocce is old, while a 28-year-old person such as Halioua is in the prime of life. Bocce is one of the lucky ones. Many dogs can only dream of living as long as he likely will, because dog lifespan is inversely correlated with body size. It’s the opposite of the wider pattern in the animal kingdom, where elephants easily outlast mice, which in turn outlive mosquitoes. A Chihuahua can expect roughly 15 years of life; an Irish wolfhound or Great Dane around seven or eight.

Halioua hopes that the startup whose name is emblazoned on her slim black T-shirt— Loyal —can start to fix this bug in humanity’s 14,000-year-plus wolf bioengineering project. The company, which she founded in 2019 and leads as CEO, is developing drugs to delay aging in dogs and extend their healthy lifespan. She has raised around $58 million and has two drugs in development. In a few years, she hopes to have the first commercial drug—for any species—to state on the label that it delays aging or extends lifespan. That alone would be a triumph, but Halioua sees it as a springboard to a still greater feat: creating similar drugs for humans.

This book explores the psychological impact of advanced forms of artificial intelligence. How will it be to live with a superior intelligence? How will the exposure to highly developed artificial intelligence (AI) systems change human well-being? With a review of recent advancements in brain–computer interfaces, military AI, Explainable AI (XAI) and digital clones as a foundation, the experience of living with a hyperintelligence is discussed from the viewpoint of a clinical psychologist. The theory of universal solicitation is introduced, i.e. the demand character of a technology that wants to be used in all aspects of life. With a focus on human experience, and to a lesser extent on technology, the book is written for a general readership with an interest in psychology, technology and the future of our human condition. With its unique focus on psychological topics, the book offers contributions to a discussion on the future of human life beyond purely technological considerations.

Back to top.

Our cells change over our lifespan and while some of the changes are necessary and beneficial to our body, sometimes they change in a dangerous and life-threatening way.

Knowing what type of cancer mutation you have is one of the best things you can do to narrow down treatment plans and eligibility for clinical trials. A great way to do that is to get Next-Generation Sequencing (NGS) testing done.

Continue reading “Do you have the PTCH1 Mutation?” »